ReviewDiabetologia2026
Dementia in type 2 diabetes: risk factors, disease processes and opportunities for prevention across the lifespan.
Review in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with type 2 diabetes have a 60-70% higher risk of developing dementia than those without diabetes. Given the increasing number of older people living with diabetes, preventing dementia in this population is becoming increasingly important. However, dementia in individuals with type 2 diabetes is not a single entity and no diabetes-specific pathologies contributing to dementia have been identified yet. Here, we suggest that the relation between type 2 diabetes and dementia may be best understood through a probabilistic model that considers the context in which type 2 diabetes develops and the involvement of multiple dementia-related pathologies. Within this model, type 2 diabetes alters both the probability of dementia-related pathologies occurring and their downstream consequences. Opportunities for prevention of dementia evolve across the lifespan and comprise reducing cumulative exposures to dementia risk factors through a holistic approach rather than through targeting a single factor. Accordingly, beyond preventing type 2 diabetes itself, glucose-lowering medications with effects beyond glycaemic management (e.g. multihormone receptor modulators, such as glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors), alongside traditional multi-domain cardiovascular risk management, may be most effective at lowering excess dementia risk in individuals with type 2 diabetes.
Indexed as
Identifiers
42440082What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.